Bluebird bio, inc. (BLUE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Net loss

-202,611

-223,347

-206,033

-195,782

-164,446

-149,023

-145,482

-145,994

-115,126

-117,228

-78,804

-70,899

-68,712

-71,364

-77,025

-58,844

-56,274

-47,275

-42,926

-51,795

-24,787

-19,544

-17,030

-1,526

-10,609

-8,081

-6,113

-4,583

-6,544

Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of contingent consideration

-3,108

1,435

802

214

296

2,156

47

262

534

-729

-1,923

-970

1,433

576

1,098

-12

1,013

329

-173

1,973

215

-

-

-

-

-

-

-

-

Depreciation and amortization

4,880

5,056

4,547

4,048

3,783

4,545

4,414

4,179

4,020

3,639

3,618

3,437

2,844

2,516

2,385

2,464

2,283

2,038

1,872

1,799

1,710

1,670

1,541

542

475

331

306

165

139

Stock-based compensation expense

36,293

34,631

38,546

55,111

32,341

29,987

29,798

28,056

22,995

14,329

13,982

13,490

11,481

8,925

9,905

10,783

10,143

10,109

9,529

16,050

5,432

3,006

2,914

2,350

2,493

1,658

2,515

1,657

661

Unrealized loss on equity securities

-4,520

-

-

-

-3,085

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other non-cash items

1,387

1,638

2,298

3,608

3,456

8,986

-272

-431

-2,403

-5,698

211

1,496

838

-4,991

603

695

868

985

259

139

130

-

-

-

-

-

-

-

-

Issuance of restricted common stock in exchange for consulting services to non-employees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

42

-

-

-

-

Re-measurement of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

399

41

Loss on disposal of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-2

Changes in operating assets and liabilities:
Prepaid expenses and other assets

10,984

3,241

-10,022

7,901

12,793

5,274

15,735

-10,207

13,486

7,227

3,271

6,489

3,105

10,461

2,135

-549

2,271

4,130

1,658

1,057

2

-141

688

1,210

-2,064

311

2,997

-167

1,073

Operating lease right-of-use assets

5,842

-

-

-

5,374

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-9,519

320

16,628

-3,938

10,590

4,107

-4,590

4,834

-737

973

-2,450

5,260

-3,257

5,448

4,342

-937

-2,195

1,918

1,041

-87

-331

355

98

-314

-2,388

3,088

395

-823

-593

Accrued expenses and other liabilities

-20,557

31,031

24,561

12,213

-21,514

6,366

21,677

5,248

4,541

12,316

2,041

4,809

-13,318

-2,048

21,602

2,286

211

4,103

4,222

1,010

88

4,356

-2,061

5,936

1,738

-487

631

1,102

-485

Operating lease liabilities

-5,070

-

-4,584

-3,483

3,224

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-2,118

-2,118

-2,840

-3,044

-8,672

-9,891

-10,392

-7,623

-13,966

-2,060

10,766

-3,713

-3,969

-1,552

-1,552

-1,553

9,222

-1,472

-1,073

20,060

-6,344

-5,866

-6,335

-6,335

-6,335

-6,335

-6,336

-6,334

73,873

Collaboration research advancement

2,302

1,332

1,976

465

1,966

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

45

462

-

1,336

235

234

310

-160

-210

-270

-14

634

904

586

4,675

2,739

-3

-3

Net cash used in operating activities

-206,100

-158,992

-113,381

-137,873

-154,154

-129,731

-74,473

-100,400

-108,822

-95,379

-56,337

-53,534

-75,303

-69,106

-39,441

-44,334

-36,766

-33,085

-29,067

-12,118

-24,159

-15,664

-20,771

-11,324

-11,934

-5,455

-8,860

-8,253

66,018

Cash flows from investing activities:
Purchase of property, plant and equipment, including assets under financing lease obligation

10,676

12,390

20,713

18,604

19,321

12,893

22,155

13,237

7,452

18,834

3,899

13,485

26,024

13,024

8,948

2,163

3,894

3,437

1,050

1,412

1,156

2,405

1,769

2,017

2,517

5,290

2,115

453

812

Purchases of marketable securities

101,421

109,633

175,572

89,630

381,735

690,819

138,000

286,750

402,413

-

-

33,800

82,940

203,090

64,290

52,670

28,175

284,676

209,059

38,420

223,020

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

336,675

306,276

329,550

340,660

364,143

262,604

214,040

272,500

145,140

111,626

109,380

106,300

104,510

86,680

129,859

130,310

96,515

66,940

69,559

31,480

31,200

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

224,578

183,253

129,041

232,426

-36,913

-421,091

33,868

-27,487

-264,725

27,592

-398,783

59,015

-4,454

-132,555

59,533

75,686

64,446

-221,173

-149,725

-7,993

-192,976

27,595

-175,581

-6,690

-2,517

-5,290

-2,015

-1,706

-812

Reimbursement of assets under financing lease obligation

-

-

-

-

-

0

0

0

3,098

0

1,622

22,568

13,831

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on financing lease obligation

-

-

-

-

-

289

282

340

106

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock

-

-

-

-

-

1

600,665

1

48,701

992,164

5,767

5,599

3,040

231,176

2,433

714

639

1,200

3,388

3,057

2,464

2,851

479

1,225

671

-

-

-

-

Accumulated issuance costs of planned initial public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

415

Proceeds from exercise of stock options and ESPP contributions

963

2,005

4,178

4,781

10,223

2,209

3,926

5,640

19,984

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

31

34

Net cash provided by financing activities

963

2,005

4,178

4,781

10,223

1,921

658,793

5,301

71,677

588,331

6,120

464,852

16,871

239,773

2,433

-1,311

639

1,017

3,003

480,236

2,464

246,311

110,245

1,225

671

233

-1,181

106,970

-381

Increase (decrease) in cash, cash equivalents and restricted cash

19,420

26,282

19,838

99,334

-180,844

-548,901

618,188

-122,586

-301,870

520,544

-449,000

470,333

-62,886

38,112

22,525

30,041

28,319

-253,241

-175,789

460,125

-214,671

258,242

-86,107

-16,789

-13,780

-10,512

-12,056

97,011

64,825

Supplemental cash flow disclosures from investing and financing activities:
Assets acquired under financing lease obligation

-

-

-

-

-

-

-

-

-

804

170

1,028

1,269

-

-

12,212

12,513

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property, plant and equipment included in accounts payable and accrued expenses

1,125

-1,325

-2,258

-433

9,302

4,679

-5,045

4,998

2,817

826

546

-4,777

5,971

3,884

1,570

-177

1,086

614

951

-601

1,125

-911

954

-603

947

577

1,066

121

160

Right-of-use assets obtained in exchange for operating lease liabilities

14,425

-

-

-

5,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Tenant improvements included in receivables and other current assets

1,516

-

-

-

8,009

-

-

-

14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental cash flow disclosures:
Tenant improvements under financing lease included in tenant improvements receivable

-

-

-

-

-

-

-

-

-

-

-1,622

-9,052

12,687

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

992